Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year Low at $24.17

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $24.17 and last traded at $24.44, with a volume of 13150 shares trading hands. The stock had previously closed at $24.58.

Analyst Ratings Changes

Several equities research analysts have issued reports on MIRM shares. Raymond James lowered their price target on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 19th. HC Wainwright reissued a “buy” rating and issued a $58.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. SVB Leerink cut their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Monday, March 18th. JMP Securities upped their price objective on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $52.11.

View Our Latest Stock Report on MIRM

Mirum Pharmaceuticals Stock Performance

The stock’s 50 day moving average price is $27.21 and its 200 day moving average price is $28.70. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The company has a market capitalization of $1.15 billion, a P/E ratio of -6.19 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The firm had revenue of $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.12 EPS for the current year.

Insider Activity

In related news, COO Peter Radovich sold 4,303 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the transaction, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Eric Bjerkholt acquired 2,000 shares of the company’s stock in a transaction on Wednesday, March 27th. The stock was acquired at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the purchase, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $347,200. The disclosure for this purchase can be found here. Insiders own 24.06% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 10.8% in the first quarter. Los Angeles Capital Management LLC now owns 41,836 shares of the company’s stock valued at $1,051,000 after purchasing an additional 4,069 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Mirum Pharmaceuticals by 111.9% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 211,949 shares of the company’s stock worth $6,257,000 after buying an additional 111,949 shares during the last quarter. Vanguard Group Inc. increased its holdings in Mirum Pharmaceuticals by 46.2% during the fourth quarter. Vanguard Group Inc. now owns 2,476,244 shares of the company’s stock worth $73,099,000 after buying an additional 782,901 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Mirum Pharmaceuticals by 89.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 456,318 shares of the company’s stock worth $13,471,000 after buying an additional 215,542 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Mirum Pharmaceuticals by 3,544.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,164,682 shares of the company’s stock worth $34,383,000 after purchasing an additional 1,132,723 shares during the period.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Recommended Stories

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.